Bayer teams with WHF
This article was originally published in The Tan Sheet
Executive SummaryThe World Heart Federation and aspirin manufacturer Bayer HealthCare have entered into a three-year partnership to "combat the rising global burden of cardiovascular disease," the corporations announce Sept. 6. The partners will educate the public and healthcare professionals on the risks of heart disease, will "help implement the Principles for National and Regional Guidelines on CVD Prevention" and will "develop initiatives aimed at primary and secondary prevention," including the promotion of low-dose aspirin for people at moderate to high risk., WHF states...
You may also be interested in...
The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.
US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.
FDA seems poised to approve the drug for the orphan eye disease called TED, but remains concerned about labeling for some adverse events.